Targeting neuropilin-1 in human leukemia and lymphoma

Blood

Volumn 117, Issue 3, 2011, Pages 920-927

  Karjalainen, Katja ^a,b   Jaalouk, Diana E ^a   Bueso Ramos, Carlos E ^a   Zurita, Amado J ^a   Kuniyasu, Akihiko ^a,c   Eckhardt, Bedrich L ^a   Marini, Frank C ^a   Lichtiger, Benjamin ^a   O'Brien, Susan ^a   Kantarjian, Hagop M ^a   Cortes, Jorge E ^a   Koivunen, Erkki ^a   Arap, Wadih ^a   Pasqualini, Renata ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; NEUROPILIN 1; PEPTIDE LIBRARY; PEPTIDOMIMETIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW CULTURE; CANCER CELL CULTURE; CELL SCREENING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MOTIF;

EID: 78751687553     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-282921     Document Type: Article

References (49)

1. Jäger S, Jahnke A, Wilmes T, et al. Leukemia targeting ligands isolated from phage display peptide libraries. Leukemia. 2007;21(3):411-420. (Pubitemid 46306552)
2. Takahashi S, Mok H, Parrott MB, et al. Selection of chronic lymphoblastic leukemia binding peptides. Cancer Res. 2003;63(17):5213-5217. (Pubitemid 37139830)
3. McGuire MJ, SamLi KN, Chang YC, Brown KC. Novel ligands for cancer diagnosis: Selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp Hematol. 2006;34(4):443-452.
4. Koivunen E, Ranta TM, Annila A, et al. Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. J Cell Biol. 2001;153(5):905-916.
5. Stefanidakis M, Karjalainen K, Jaalouk DE, et al. Role of leukemia cell invadosome in extramedullary infiltration. Blood. 2009;114(14):3008-3017.
6. Nishimura S, Takahaski S, Kamikatahira H, et al. Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells. J Biol Chem. 2008;283(17):11752-11762.
7. Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med. 2001;7(11):1249-1253. (Pubitemid 33063782)
8. Christianson DR, Ozawa MG, Pasqualini R, Arap W. Techniques to decipher molecular diversity by phage display. Methods Mol Biol. 2007;357:385-406. (Pubitemid 350183263)
9. Kolonin MG, Bover L, Sun J, et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res. 2006;66(1):34-40. (Pubitemid 43166005)
10. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilin in neoplasms: Expression, regulation, and function. Exp Cell Res. 2006;312(5):584-593.
11. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5(9):1032-1038. (Pubitemid 29439574)
12. Pileri SA, Ascani S, Milani M, et al. Acute leukaemia immunophenotyping in bone-marrow routine sections. Br J Hematol. 1999;105(2):394-401. (Pubitemid 29232160)
13. Pulli T, Koivunen E, Hyypiä T. Cell-surface interaction of Echovirus 22*. J Biol Chem. 1997;272(34):21176-21180.
14. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17(8):768-774. (Pubitemid 29365104)
15. Berntzen G, Brekke OH, Mousavi SA, et al. Characterization of an FcγRI-binding peptide selected by phage display. Protein Eng Des Sel. 2006;19(3):121-128.
16. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380(6572):364-366. (Pubitemid 26097120)
17. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A. 2009;106(38):16157-16162.
18. Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328(5981):1031-1035.
19. Hong TM, Chen YL, Wu YY, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res. 2007;13(16):4759-4768. (Pubitemid 47294782)
20. Giordano RJ, Anobom CD, Cardó-Vila M, et al. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. Chem Biol. 2005;12(10):1075-1083. (Pubitemid 41483625)
21. Giordano RJ, Cardó-Vila M, Salameh A, et al. From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathway. Proc Natl Acad Sci U S A. 2010;107(11):5112- 5117.
22. Barr MP, Byrne AM, Condron CM, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1- expressing breast tumor cells. B J Cancer. 2005;92(2):328-333.
23. Kawakami A, Kitsukawa T, Takagi S, Fujisawa H. Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system. J Neurobiol. 1996;29(1):1-17. (Pubitemid 26021768)
24. Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev. 2001;109(1):115-119. (Pubitemid 33035924)
25. Gu C, Rodriguez ER, Reimert DV, et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell. 2003;5(1):45-57. (Pubitemid 36827341)
26. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell. 1997;90(4):739-751. (Pubitemid 27357965)
27. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell. 1997;90(4):753-762.
28. Klagsbrun M, Takashima S, MamLuk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol. 2002;515:33-48. (Pubitemid 36324180)
29. Takahashi T, Fournier A, Nakamura F, et al. Plexin-neuropilin 1 complexes form functional semaphorin-3A receptors. Cell. 1999;99(1):59-69. (Pubitemid 29468630)
30. Neufeld G, Kessler O, Herzog Y. The interaction of neuropilin-1 and neuropilin-2 with tyrosinekinase receptors for VEGF. Adv Exp Med Biol. 2002;515:81-90. (Pubitemid 36324184)
31. West DC, Rees CG, Duchesne L, et al. Interaction of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem. 2005;280(14):13457-13464. (Pubitemid 40517234)
32. Wülfing C, Rupp F. Neuropilin-1: another neuronal molecule in the "immunological synapse." Nat Immunol. 2002;3(5):418-419.
33. Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol. 2002;3(5):477-482. (Pubitemid 34520798)
34. Brusselmans K, Bono F, Collen D, Herbert JM, Carmeliet P, Dewerchin M. A novel role for vasculature endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem. 2005;280(5):3493-3499. (Pubitemid 40223814)
35. Matthies AM, Low QEH, Lingen MW, DiPietro LA. Neuropilin-1 participates in wound angiogenesis. Am J Pathol. 2002;160(1):289-296.
36. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410.
37. Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett. 2006;231(1):1-11. (Pubitemid 41779447)
38. Pan Q, Chanthery Y, Liang WC, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 2007;11(1):53-67. (Pubitemid 46054517)
39. Hansel DE, Wilentz RE, Yeo CJ, Schulick RD, Montgomery E, Maitra A. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastasis of the human gastrointestinal tract. Am J Surg Pathol. 2004;28(3):347-356. (Pubitemid 38269568)
40. Latil A, Bieche I, Pesche S, et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer. 2000;89(2):167-171. (Pubitemid 30185926)
41. Bachelder RE, Crago A, Chung JC, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61(15):5736-5740. (Pubitemid 32769088)
42. Padró T, Ruiz S, Bieker R, Bü et et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637-2644.
43. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95(1):309-313. (Pubitemid 30017257)
44. Vales A, KondoR, Aichberger KJ, et al. Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma. 2007;48(10):1997-2007. (Pubitemid 47542987)
45. Yamada Y, Oike Y, Ogawa H, et al. Neuropilin-1 on hematopoietic cells as a source of vascular development. Blood. 2003;101(5):1801-1809. (Pubitemid 36237577)
46. Kreuter M, Woelke K, Bieker R, et al. Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia. 2006;20(11):1950-1954. (Pubitemid 44614883)
47. Lu L, Zhang L. Xiao ZJ, Lu SH, Yang RC, Han ZC. Neuropilin-1 in acute myeloid leukemia: Expression and role in proliferation and migration of leukemia. Leuk Lymphoma. 2008;49(2):331-338. (Pubitemid 351193927)
48. Schuch G, Machluf M, Bartsch G, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin 1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood. 2002;100(13):4622-4628.
49. Konopleva M, Tabe Y, Zeng Z, Andreef M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009;12(4-5):103-113.